Qualys Chairman and Chief Executive Officer Philippe Courtot to Take a Medical Leave of Absence
Sumedh Thakar, Qualys President and Chief Product Officer, Appointed Interim CEO
News provided by
Share this article
Share this article
FOSTER CITY, Calif., Feb. 10, 2021 /PRNewswire/ Qualys, Inc. (NASDAQ: QLYS), a pioneer and leading provider of disruptive cloud-based IT, security and compliance solutions, today announced Philippe Courtot, chairman of the board and chief executive officer (CEO), is taking a leave of absence due to health issues unrelated to COVID-19. Qualys Board of Directors appointed Sumedh Thakar, president and chief product officer, as interim CEO and principal executive officer on February 7, 2021. The Board also appointed Thakar to serve on the Board as a Class III director until Qualys 2021 annual meeting of stockholders, or until his successor is duly elected and qualified.
Press release content from Accesswire. The AP news staff was not involved in its creation.
Evotec And Related Sciences Enter Integrated Drug Discovery and Development Partnership
February 9, 2021 GMT
PARTNERSHIP COMBINES RELATED SCIENCES’ COLLABORATIVE SCIENCE MODEL AND DATA-DRIVEN APPROACH TO IDENTIFYING BIOLOGICAL BREAKTHROUGHS WITH EVOTEC’S INTEGRATED PLATFORM TO DRIVE INNOVATIVE MULTIMODALITY DRUG DISCOVERY FROM TARGET TO CLINIC
EVOTEC WILL BENEFIT FROM SUCCESS THROUGH MILESTONES, ROYALTIES AND FOUNDING EQUITY STAKES IN ALL RELATED SCIENCES ASSETS DEVELOPED WITHIN THIS COLLABORATION
HAMBURG, GERMANY / ACCESSWIRE / February 9, 2021 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that the Company has entered into an integrated multi-target drug discovery agreement with biotech venture creation firm Related Sciences to generate multiple drug development candidates, biomarkers, and IND filings over a multi-year period.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Amicus Therapeutics Announces Positive Initial Clinical Data for CLN3 Batten Disease Gene .
Amicus Therapeutics, Inc.February 8, 2021 GMT
Initial Data Suggest Early Signs of Disease Stabilization in Children with
Fatal Neurologic Disease
Plan to Submit IND for Next Clinical Study in 2H2021
PHILADELPHIA, Feb. 08, 2021 (GLOBE NEWSWIRE) Amicus Therapeutics (Nasdaq: FOLD) today announced positive initial results from its first in-human study of its CLN3 Batten disease gene therapy program, AT-GTX-502. The results are featured in a virtual poster presentation at the 17th Annual WORLD
Symposium ™ 2021, being held February 8-12, 2021. The poster is also available in the Events and Presentations section of the Amicus Therapeutics corporate website.
VANS Brand Showcase Store Gangnam Creates an Authentic Experience With HARMAN Professional Solutions
By
Staff
1 month ago
TechDataPS Co., Ltd. equips the iconic footwear brand’s new Seoul location with a sophisticated networked audio system spanning two floors
SEOUL, South Korea TechDataPS Co., Ltd. recently equipped the new VANS Brand Showcase Store in Seoul’s Gangnam district with a HARMAN Professional Solutions audio system spanning two floors and featuring JBL loudspeakers, Crown amplifiers and dbx zone processors.
In addition to being a retail outlet for the brand’s extensive footwear and apparel line, VANS Brand Showcase Store Gangnam aims to immerse visitors in the company’s history and style. The first floor features a “shoppable timeline” of throwback merchandise, books, vinyl records and more, as well as a DJ booth and a functioning wall of vintage loudspeakers. The second floor houses a “customization zone” where customers can design and personalize
Evotec AG: Evotec and Medical Center Hamburg-Eppendorf Enter Partnership to Develop iPSC-Based Tissue Therapy for Heart Failure
RISK-REWARD-SHARING PARTNERSHIP LEVERAGES COMPLEMENTARY PLATFORMS
HAMBURG, GERMANY / ACCESSWIRE / February 4, 2021 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that the Company has entered into a multi-year partnership with the Medical Center Hamburg-Eppendorf ( UKE ) for the development of a highly innovative first-in-class cell therapy approach for the treatment of heart failure.
Under the terms of the partnership, Evotec and UKE will leverage their complementary strengths for the development of a new cell therapy approach using Engineered Heart Tissue for the treatment of heart failure. Heart failure is frequently associated with ischemic heart disease and often comes with a poor prognosis. Mortality is comparable to that of the most common cancers, with